Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 7/20 | 0.66 |
| ▸ | NPC1 | O15118 | 6/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | SCD | O00767 | 6/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL544557 | 0.90 | LMNA (0.68) | LMNARAB9ANPC1SMN1; SMN2DYRK1A | |
| SCHEMBL15271353 | 0.82 | DYRK1A (0.80) | LMNARAB9ANPC1SMN1; SMN2DYRK1A | |
| Tioxidazole SCHEMBL23382 | 0.81 | LMNA (1.00) | LMNARAB9ANPC1SMN1; SMN2DYRK1A | |
| Tioxidazole SCHEMBL1033860 | 0.81 | LMNA (1.00) | LMNARAB9ANPC1SMN1; SMN2DYRK1A | |
| SCHEMBL14375445 | 0.81 | SCD (0.66) | LMNARAB9ANPC1SMN1; SMN2DYRK1A | |
| SCHEMBL14113317 | 0.81 | DYRK1A (0.74) | LMNARAB9ANPC1SMN1; SMN2DYRK1A | |
| Tioxidazole SCHEMBL3053813 | 0.80 | LMNA (0.98) | LMNARAB9ANPC1SMN1; SMN2DYRK1A | |
| SCHEMBL10170615 | 0.80 | DYRK1A (0.80) | RAB9ANPC1SMN1; SMN2DYRK1ACYP1A2 | |
| SCHEMBL16747427 | 0.80 | RAB9A (0.71) | LMNARAB9ANPC1SMN1; SMN2DYRK1A | |
| Tioxidazole SCHEMBL21192520 | 0.79 | LMNA (0.95) | LMNARAB9ANPC1SMN1; SMN2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110571-B2 | Tyrosine kinase inhibitors; antiproliferation agents; metabolism diseases; antiallergens; central nervous system disorders; vision and skin disorders; antiarthritic agents | AVENTIS PHARMA S.A. (FR) | 2012-02-07 | — | — | US | disclosed |
| US-20080194555-A1 | Novel Benzimidazole and Benzothiazole Derivatives, Method for Preparing Same, Use Thereof as Drugs, Pharmaceutical Compositions and Novel Use Especially as c-MET Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194555-A1 | Novel Benzimidazole and Benzothiazole Derivatives, Method for Preparing Same, Use Thereof as Drugs, Pharmaceutical Compositions and Novel Use Especially as c-MET Inhibitors | MET, KIT, MERTK | LMNA 4033/4885RAB9A 3640/4885NPC1 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.